Patent US4348384A successfully refreshed from Google Patents.
US4348384A
Expired / Lapsed
US
⏱️ 0.0 years remaining
Pharmaceutical composition for oral administration containing coagulation factor VIII or IX
Assignee: Sumitomo Pharma Co Ltd
•
Filing: 1981-10-07
•
Granted: 1982-09-07
•
Expires: 2001-10-07
Abstract
Abstract A pharmaceutical composition suitable for the treatment and prophylaxis of hemophilia A or B, which comprises coagulation factor VIII or IX and a protease inhibitor (particularly aprotinin) which are incorporated in liposomes and optionally lyophilized and/or encapsulated in intestine capsules. The composition can give high absorption of the required coagulation factor from intestinal tract without being decomposed in gastrointestinal tract even by administration in oral route.
Inventors
- 👤 Isamu Horikoshi
- 👤 Nobuo Sakuragawa
- 👤 Masaharu Ueno
- 👤 Kaoru Takahashi
Bibliographic Details
Application Number
—
Jurisdiction
US
Data Source
google_patents
Last Synchronized
2026-10-23 17:02
CPC Classifications
C; C07; C07K; C07K14/00; C07K14/435; C07K14/745; C07K14/755; A; A61; A61K; A61K38/00; A61K38/16; A61K38/17; A61K38/36; A61K38/37; A61K9/00; A61K9/10; A61K9/127
Claims Analysis
Total Claims: 19
Claim 1
Independent Claim
25 words
A pharmaceutical composition for oral administration, which comprises effective amounts of coagulation factor VIII or IX and a protease inhibitor which are incorporated in liposomes.
Claim 2
Dependent Claim
25 words
A pharmaceutical composition for oral administration, which comprises effective amounts of coagulation factor VIII or IX and a protease inhibitor which are incorporated in liposomes.
Claim 3
Dependent Claim
14 words
A composition according to claim 1, wherein the composition is encapsulated in intestine capsules.
Claim 4
Dependent Claim
17 words
A composition according to claim 1, wherein the composition is in the form of a lyophilized product.
Claim 5
Dependent Claim
14 words
A composition according to claim 3, wherein the composition is encapsulated in intestine capsules.
Claim 6
Dependent Claim
14 words
A composition according to claim 1, wherein the coagulation factor is coagulation factor VIII.
Claim 7
Dependent Claim
14 words
A composition according to claim 5, wherein the composition is encapsulated in intestine capsules.
Claim 8
Dependent Claim
14 words
A composition according to claim 1, wherein the coagulation factor is coagulation factor IX.
Claim 9
Dependent Claim
27 words
A pharmaceutical composition for oral administration, which comprises effective amounts of coagulation factor VIII or IX, a protease inhibitor, and liposome-forming material, which are each separately lyophilized.
Claim 10
Dependent Claim
27 words
A pharmaceutical composition for oral administration, which comprises effective amounts of coagulation factor VIII or IX, a protease inhibitor, and liposome-forming material, which are each separately lyophilized.
Claim 11
Dependent Claim
15 words
A composition according to claim 8, wherein the lyophilized products are encapsulated in intestine capsules.
Claim 12
Dependent Claim
40 words
A pharmaceutical composition for oral administration in the form encapsulated in intestine capsules, which comprises effective amounts of coagulation factor VIII or IX and aprotinin which are incorporated in liposomes formed from a mixture of a phospholipid and phosphatidic acid.
Claim 13
Dependent Claim
40 words
A pharmaceutical composition for oral administration in the form encapsulated in intestine capsules, which comprises effective amounts of coagulation factor VIII or IX and aprotinin which are incorporated in liposomes formed from a mixture of a phospholipid and phosphatidic acid.
Claim 14
Dependent Claim
14 words
A composition according to claim 10, wherein the coagulation factor is coagulation factor VIII.
Claim 15
Dependent Claim
13 words
A composition according to claim 10, wherein the coagulation is coagulation factor IX.
Claim 16
Dependent Claim
39 words
A lyophilized pharmaceutical composition for oral administration in the form encapsulated in intestine capsules, which comprises effective amounts of coagulation factor VIII and aprotinin which are incorporated in liposomes formed from a mixture of a phospholipid and phosphatidic acid.
Claim 17
Dependent Claim
39 words
A lyophilized pharmaceutical composition for oral administration in the form encapsulated in intestine capsules, which comprises effective amounts of coagulation factor VIII and aprotinin which are incorporated in liposomes formed from a mixture of a phospholipid and phosphatidic acid.
Claim 18
Independent Claim
48 words
A method for the treatment and prophylaxis of hemophilia A or B, which comprises administering orally a composition comprising effective amounts of coagulation factor VIII or IX and a protease inhibitor which are incorporated in liposomes to a patient who are deficient in coagulation factor VIII or IX.
Claim 19
Independent Claim
48 words
A method for the treatment and prophylaxis of hemophilia A or B, which comprises administering orally a composition comprising effective amounts of coagulation factor VIII or IX and a protease inhibitor which are incorporated in liposomes to a patient who are deficient in coagulation factor VIII or IX.
References Cited (Backward Citations)
US4183960A
Cited
USPTO Annuity & Maintenance Windows
| Annuity Stage | Window Opens | Payment Deadline | Surcharge Period Until | Estimated Fee | Status |
|---|---|---|---|---|---|
| 3.5 Years (Year 4) | 1985-09-06 | 1986-03-08 | 1986-09-07 | $2000.00 | Window Closed / Lapsed |
| 7.5 Years (Year 8) | 1989-09-06 | 1990-03-08 | 1990-09-07 | $3760.00 | Window Closed / Lapsed |
| 11.5 Years (Year 12) | 1993-09-06 | 1994-03-08 | 1994-09-07 | $7700.00 | Window Closed / Lapsed |